[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608965":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":37,"centralContacts":42,"locations":47,"responsibleParty":62,"collaborators":30,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":30,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":30,"enrollmentInfo":73,"targetDuration":30,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":86,"whyStopped":30,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"The University of Hong Kong","OTHER",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"14 Fr chest tube","EXPERIMENTAL","14Fr chest tube will be inserted",[13],"Device: 14 Fr chest tube",{"label":15,"type":16,"description":17,"interventionNames":18},"12 Fr chest tube","ACTIVE_COMPARATOR","12Fr chest tube will be inserted",[19],"Device: 12 Fr chest tube",{"label":21,"type":16,"description":22,"interventionNames":23},"8 Fr chest tube","8Fr chest tube will be inserted",[24],"Device: 8 Fr chest tube",[26,31,34],{"type":27,"name":9,"description":28,"armGroupLabels":29,"otherNames":30},"DEVICE","Chest tube size of 14Fr will be inserted",[9],null,{"type":27,"name":15,"description":32,"armGroupLabels":33,"otherNames":30},"Chest tube of 12 Fr will be inserted",[15],{"type":27,"name":21,"description":35,"armGroupLabels":36,"otherNames":30},"Chest tube size of 8Fr will be inserted",[21],[38],{"name":39,"affiliation":40,"role":41},"King Pui Florence Chan, MD","The University of Hong Kong, Queen Mary Hospital","PRINCIPAL_INVESTIGATOR",[43],{"name":39,"role":44,"phone":45,"phoneExt":30,"email":46},"CONTACT","+852 22553741","kpfchan@hku.hk",[48],{"facility":40,"status":30,"city":49,"state":30,"zip":30,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Hong Kong","China","CN",{"type":53,"coordinates":54},"Point",[55,56],114.17469,22.27832,{"lat":56,"lon":55},[59],{"name":60,"role":44,"phone":61,"phoneExt":30,"email":46},"King-Pui Florence Chan, MD","825 2255 3741",{"type":63,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100608965","pleurodesis-in-small-bore-chest-tube-100608965",false,"NCT07208409","Pleurodesis in Small-bore Chest Tube","How Small Is Small - Pleurodesis in Small-Bore Chest Tube","Inclusion Criteria:\n\n* Pleural effusion.\n* With clinical indications for pleural drainage and chest drain insertion.\n* With anticipated need for pleurodesis e.g. known malignancy, no clinical signs of pleural infection.\n* age ≥18 year-old\n\nExclusion Criteria:\n\n* Pleural effusion not sizable for drainage.\n* With clinical suspicion of pleural infection e.g. pleuritic chest pain, fever, ultrasound showed loculated pleural effusion\n* Age ≤18 year-old","ALL","18 Years",{"count":74,"type":75},60,"ESTIMATED","INTERVENTIONAL",[78],"NA","Malignant pleural effusion (MPE) imposes a high burden on the healthcare system in the Asian Pacific region, as lung and breast cancer are the commonest cancers associated with malignant pleural effusion, as the two commonest cancers in the Asian Pacific region.\n\nWhile indwelling pleural catheter (IPC), a catheter that is inserted for long-term drainage of pleural fluid, is not commonly used in Asian countries, small-bore chest tubes are increasingly used due to their ease of insertion and causing less pain.\n\nInjecting talc, a chemocal, to promote adhesion of pleura, called talc pleurodesis was an effective method of managing MPE. However, the optimal size of small-bore chest tubes and the feasibility of talc pleurodesis have not been thoroughly investigated.\n\nThis randomised controlled trial aims to evaluate the feasibility and success rate of pleurodesis using small-bore chest drains and to examine the outcomes associated with different sizes of these drains, namely 8 Fr, 12 Fr, and 14 Fr, in managing MPE.\n\nThe primary outcome is the feasibility of talc pleurodesis with different small-bore chest tubes. Secondary outcomes include the differences in recurrence rates post-pleurodesis between small-bore and ultra-small-bore chest tubes, as well as patient outcomes such as pain scores, SpO2\u002FFiO2 ratios (oxygen saturation\u002Ffractional inspired oxygen ratio), and complications.\n\nThe sample size will be 60, and the project will be carried out over one year.\n\nThe outcome of this study can serve as a reference for managing MPE regarding the feasibility, safety, and efficacy of ultra-small-bore chest tubes worldwide, particularly in the Asia-Pacific region, where IPC is less common.",[81],"Pleural Effusion, Malignant",[83,84,85],"malignant pleural effusion","pleurodesis","small bore chest tube","NOT_YET_RECRUITING","2025-12-17",{"date":89,"type":90},"2025-12-24","ACTUAL",{"date":92,"type":75},"2026-02-01",{"date":94,"type":75},"2029-01-31",{"name":5,"class":6},1]